Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Every story we pull is tagged to the disease it’s about — so you can filter to your condition and read only what matters.
Showing news related to
obesity and the risk of idiopathic pulmonary fibrosis a nationwide population based study
Original title: “Obesity and the risk of idiopathic pulmonary fibrosis: a nationwide population-based study.”
A spokesperson confirmed that a “limited number” of liver-related safety events, including a patient death, were observed in testing of Bristol’s admilparant — though it’s unclear whether the drug was to blame.
Original title: “Bristol Myers trial revisions shake confidence in new class of fibrosis drugs”
riddle syndrome with rnf168 mutation in first asian family cluster exhibiting pulmonary fibrosis and achalasia
Original title: “Riddle syndrome with RNF168 mutation in first Asian family cluster exhibiting pulmonary fibrosis and achalasia.”
exploring the autoimmune spectrum of combined pulmonary fibrosis and emphysema inflammatory myopathy cases and a systematic review
Original title: “Exploring the Autoimmune Spectrum of Combined Pulmonary Fibrosis and Emphysema: Inflammatory Myopathy Cases and a Systematic Review.”
machine learning approach to identify perspectives of people living with pulmonary fibrosis
Original title: “A machine learning approach to identify perspectives of people living with pulmonary fibrosis.”
early fibrotic remodeling remains responsive to autologous fat grafting histological findings in a rat model
Original title: “Early Fibrotic Remodeling Remains Responsive to Autologous Fat Grafting: Histological Findings in a Rat Model.”
pathophysiology of pulmonary fibrosis associated with monogenic defects of telomere homeostasis
Original title: “[Pathophysiology of pulmonary fibrosis associated with monogenic defects of telomere homeostasis].”
optimal timing duration and sequencing of therapy for progressive pulmonary fibrosis the urgent need to move beyond the wait to fail paradigm
Original title: “Optimal timing, duration and sequencing of therapy for progressive pulmonary fibrosis: the urgent need to move beyond the 'wait-to-fail' paradigm.”
effect of nerandomilast on survival in patients with pulmonary fibrosis
Original title: “Effect of nerandomilast on survival in patients with pulmonary fibrosis.”
high throughput plasma proteomics reveals circulating biomarkers of interstitial lung disease and progressive pulmonary fibrosis in systemic sclerosis
Original title: “High-throughput plasma proteomics reveals circulating biomarkers of interstitial lung disease and progressive pulmonary fibrosis in systemic sclerosis.”
progressive pulmonary fibrosis a state of the art review
Original title: “Progressive pulmonary fibrosis: a state-of-the-art review.”
expert perspectives defining and managing progressive pulmonary fibrosis in systemic sclerosis
Original title: “Expert Perspectives: Defining and managing progressive pulmonary fibrosis in systemic sclerosis.”
EMA has recommended granting a marketing authorisation in the European Union (EU) for Jascayd (nerandomilast) to treat adults with idiopathic pulmonary fibrosis (IPF) or…
Original title: “New medicine for two types of pulmonary fibrosis”
The biotechnology startup emerged from stealth with a peptide drug it claims to have the potential to reverse lung scarring in people with idiopathic pulmonary fibrosis.
Original title: “Oorja, run by Acceleron veterans, launches to make new fibrosis drugs”
In this episode of Denatured, you'll be hearing from Georg Vo Beiske, CEO of Tribune Therapeutics and Jonas Hallén, co-founder and Chief Medical Officer of Calluna Pharma. We dive into IPF and fibrosis challenges, unpacking treatment hurdles, emerging targets, unmet needs and expansion paths beyond the lung.
Original title: “Fibrosis, IPF and the search for better therapies”
efficacy and safety of nerandomilast in patients with autoimmune disease related progressive pulmonary fibrosis in the fibroneer ild trial
Original title: “Efficacy and safety of nerandomilast in patients with autoimmune disease-related progressive pulmonary fibrosis in the FIBRONEER-ILD trial.”
pulmonary fibrosis with a rare sftpc variant c 304g a p val102met a case report
Original title: “Pulmonary fibrosis with a rare SFTPC variant (c.304G>A, p.Val102Met): A case report.”
Analysts are cautiously optimistic about an IPO rebound for biopharma. BioSpace is keeping track of companies that seek to trade on the public markets this year.
Original title: “Avalyn plots IPO to push inhaled pulmonary fibrosis pipeline through clinic”
efficacy and safety of danazol for pulmonary fibrosis or bone marrow failure associated with telomere related gene mutation
Original title: “Efficacy and safety of danazol for pulmonary fibrosis or bone-marrow failure associated with telomere-related gene mutation.”
analysis of body composition with bioelectrical impedance analysis in different subtypes of pulmonary fibrosis
Original title: “Analysis of body composition with bioelectrical impedance analysis in different subtypes of pulmonary fibrosis.”